 SOMERSET, N.J.--BUSINESS WIRE--- LEGN CARTcell--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, has announced that the U.S. Food and Drug Administration FDA has accepted for priority review the Biologics License Application BLA submitted by Janssen Biotech, Inc. Janssen for ciltacabtagene autoleucel cilta-cel, an investigational B-cell matur 